Browse > Article

Comparison of Effectiveness and Adverse Reactions between Isoniazid 300 mg and 400 mg in Korean Patients with Pulmonary Tuberculosis  

Park, I-Nae (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center)
Hong, Sang-Bum (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center)
Oh, Yeon-Mok (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center)
Lim, Chae-Man (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center)
Lee, Sang Do (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center)
Koh, Younsuck (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center)
Kim, Woo Sung (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center)
Kim, Dong Soon (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center)
Kim, Won Dong (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center)
Shim, Tae Sun (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center)
Publication Information
Tuberculosis and Respiratory Diseases / v.60, no.1, 2006 , pp. 44-48 More about this Journal
Abstract
Background : Isoniazid (INH) is one of the most effective anti-tuberculosis (TB) drugs. In Korea, the dose of INH normally used in patients over 50 kg is 400 mg/day, which differs from the dose recommended by other countries. Indeed, the metabolism of INH shows ethnic variations, and Koreans are predominantly rapid acetylators. However, two reports suggested 300 mg of INH might be sufficient to reach an ideal peak level in Korean patients over 50 kg. Therefore, the aim of this study was to compare the effectiveness and adverse reactions between INH 300 mg and 400 mg in Korean TB patients. Method : Patients who were culture-positive, susceptible to all 1st-line drugs, initially on HREZ, and weighed over 50 kg were selected from patients with pulmonary TB between April 2003 and March 2005. The treatment results and adverse reactions in the INH 300 mg and 400 mg group were compared. Since April 2004, most TB patients at Asan Medical Center were administered INH 300 mg irrespective of the body weight. Results : The study included 123 patients in the 300 mg INH group and 128 in the 400 mg INH group. There were no significant differences between the groups in terms of age, gender, weight, history of TB treatment, initial smear strength, and frequency of cavitary lesions. There was no difference in the treatment duration between the groups. One hundred eleven (90%) patients in the INH 300 mg group and 102 (80%) in the INH 400 mg group completed treatment (p>0.05). There were no differences in the frequency of modification of the initial regimen between groups due to any adverse reactions (300 mg : 9.0%, 400 mg : 13.7%) and hepatotoxicity (300 mg : 2.7% ; 400 mg : 7.8%). Conclusion : Considering treatment results and adverse reactions of two groups, 300mg of INH may be sufficient for treating Korean TB patients. Further studies comparing the frequency of relapse will be needed.
Keywords
Tuberculosis; Isoniazid; Acetylator phenotype; Treatmenrt;
Citations & Related Records

Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/ Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-62   DOI   ScienceOn
2 Kergueris MF, Bourin M, Larousse C. Pharmacokinetics of isoniazid: influence of age. Eur J Clin Pharmacol 1986;30:335-40   DOI   ScienceOn
3 Ahn SJ, Park SJ, Kang KW, Suh GY, Chung MP, Kim H, et al. Pharmacokinetic profiles of isoniazid and rifampicin in Korean tuberculosis patients. Tuberc Respir Dis 1999;47:442-50   DOI
4 World Health Organization. Treatment of tuberculosis: guidelines for national tuberculosis programme. 3rd ed. 2003
5 Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993;329:784-91   DOI   ScienceOn
6 Lee HS, Song HS, Lee HK, Kim KH, Chung HS, Kim CK, et al. Isoniazid metabolism and its clinical implications in Koreans. Tuberc Respir Dis 1962;12:22-37
7 Ellard GA. The potential clinical significance of the isoniazid acetylator phenotype in the teatment of pulmonary tuberculosis. Tubercle 1984;65:211-27   DOI   ScienceOn
8 Chung MP, Kim HC, Suh GY, Park JW, Kim H, Kwon OJ, et al. Pharmacokinetic study of isoniazid and rifampicin in healthy Korean volunteers. Tuberc Respir Dis 1997;44:479-92   DOI
9 Frieden TR, Sherman LF, Maw KL, Fujiwara PI, Crawford JT, Nivin B, et al. A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. JAMA 1996;276:1229-35   DOI   ScienceOn
10 Korea Center for Disease Control and Prevention. Guidelines for the management of tuberculosis 2004
11 Korea Academy of Tuberculosis and Respiratory Disease. Guidelines for the management of pulmonary tuberculosis, 1997. Tuberc Respir Dis 1997;47:1447- 53
12 Armstrong AR, Peart HE. A comparison between the behavior of the Eskimos and non-Eskimos to the administration of INH. Am Rev Resp Dis 1960;81:588-94
13 Harris HW, Knight PA, Selin MJ. Comparisons of isoniazid concentrations in the blood of people of Japanes and European descent. Am Rev Tuberc 1958;78: 944-8
14 Peloquin CA. Pharmacology of the antimycobacterial drugs. Med Clin North Am 1993;77:1253-62   DOI
15 Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998;53:536-48   DOI   ScienceOn